STAT+: A longtime health care investor on the wild ride of 2020 and what to expect in 2021
It’s time to talk about biotech and 2021. What will the year ahead look like for biotech and pharma companies and for the investors who finance the drugs they develop?
Adam Kopple, a longtime health care investor and industry executive, joined STAT’s biotech podcast, “The Readout Loud” to try to answer that question. Four years ago, he co-founded Bain Capital Life Sciences, a Boston-based life sciences investment fund with more than $2 billion in assets under management.
